Systemic Sclerosis Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight | Boehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharma, Kyowa Kirin, GSK, AstraZeneca, Amgen

The Key Systemic Sclerosis Companies in the market incli d eBoehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharmaceutical, Kyowa Kirin, GSK, AstraZeneca, Amgen, Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, Kyverna Therapeutics, Cabaletta Bio, and others
DelveInsight's report, "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Systemic Sclerosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Systemic Sclerosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Systemic Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Sclerosis Market Forecast [https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Systemic Sclerosis Market Report:

*
The systemic sclerosis market size was valued at approximately USD 1,937 million in 2025 and is projected to reach around USD 2,660 million by 2034, growing at a CAGR of 3.6% over the study period (2020-2034).

*
In March 2026, Aisa Pharma, Inc., a clinical-stage biopharmaceutical company developing treatments for systemic sclerosis, announced results from its Phase II RECONNOITER trial evaluating AISA-021 (cilnidipine), a novel once-daily calcium channel blocker, for systemic sclerosis-associated Raynaud's phenomenon (SSc-RP). The findings were presented during an oral session at the 9th World Systemic Sclerosis Congress, held in Athens, Greece, from March 5-7, 2026.

*
In June 2025, aTyr Pharma announced interim Phase II EFZOCONNECT trial results for efzofitimod, demonstrating favorable safety and tolerability, along with stable or improved mRSS across all patients, meaningful clinical benefits in diffuse SSc-ILD, and promising biomarker responses.

*
In April 2025, Calibr-Skaggs Institute for Innovative Medicines (Scripps Research) received FDA clearance for their IND application to study switchable CAR-T therapy (CLBR001 + SWI019) in autoimmune diseases. The upcoming Phase 1 trial will assess safety and efficacy in patients with myositis, systemic sclerosis, lupus, and rheumatoid arthritis, with plans to potentially expand to other conditions.

*
In February 2025, the FDA cleared Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogenic CAR-T cell therapy. Researchers are set to begin the Phase 1 RESOLUTION trial in mid-2025 for autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.

*
The US accounts for the largest market size of systemic sclerosis among the 7MM in 2024, i.e., nearly 75%.

*
According to DelveInsight's estimates, between EU4 and the UK, Italy accounted for the largest market of systemic sclerosis in 2024, while Spain accounted for the least with around in the respective year.

*
In the current market, the majority of the share was accounted for by vasoactive drugs in the US, which was around USD 1,180 million in 2024.

*
RITUXAN and ACTEMRA, whose primary patents have expired, face biosimilar competition in several indications, impacting their overall sales significantly.

*
Based on DelveInsight's assessment in 2024, the 7MM had approximately 231,200 diagnosed prevalent cases of systemic sclerosis. These cases are projected to increase during the forecast period.

*
Among EU4 and the UK, Italy had the highest number of diagnosed prevalent cases of systemic sclerosis, while Spain had the lowest number of diagnosed prevalent cases.

*
It is observed that systemic sclerosis occurs majorly in the age group of 40-69 years.

*
Systemic sclerosis severity is distributed by organ damage and skin thickness. Mild organ damage and mild skin thickness are present in a majority of patients with systemic sclerosis.

*
Analysis of age-specific data in the US indicates that systemic sclerosis was least prevalent among individuals aged 39 years or younger, with the highest number of diagnosed cases observed in those aged between 40 and 69 years.

*
Key Systemic Sclerosis Companies: Boehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharmaceutical, Kyowa Kirin, GSK, AstraZeneca, Amgen, Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, Kyverna Therapeutics, Cabaletta Bio, and others

*
Key Systemic Sclerosis Therapies: OFEV (nintedanib), ACTEMRA (tocilizumab), RITUXAN (rituximab), LUMICEF (brodalumab/KHK-4827), BENLYSTA (belimumab), SAPHNELO (anifrolumab), UPLIZNA (inebilizumab/MT-0551), Vixarelimab (RG6536), Avenciguat (BI 685509), KYV 101, CABA-201, RO7303509, and others

*
The Systemic Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Sclerosis pipeline products will significantly revolutionize the Systemic Sclerosis market dynamics.

Systemic Sclerosis Overview

Systemic Sclerosis (SSc), also known as scleroderma, is a rare autoimmune disorder that causes the body's immune system to attack its own tissues, leading to thickening and hardening of the skin and connective tissues. This can affect various organs, including the lungs, heart, kidneys, and digestive system. SSc is characterized by fibrosis (scarring) and can result in restricted blood flow, leading to symptoms like skin tightening, difficulty in movement, organ dysfunction, and severe complications if left untreated. It is classified into two main types: limited and diffuse, based on the extent of skin involvement and organ involvement.

Get a Free sample for the Systemic Sclerosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/systemic-sclerosis-market [https://www.delveinsight.com/report-store/systemic-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Systemic Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Systemic Sclerosis Epidemiology Segmentation:

The Systemic Sclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Systemic Sclerosis

*
Prevalent Cases of Systemic Sclerosis by severity

*
Gender-specific Prevalence of Systemic Sclerosis

*
Diagnosed Cases of Episodic and Chronic Systemic Sclerosis

Download the report to understand which factors are driving Systemic Sclerosis epidemiology trends @ Systemic Sclerosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Systemic Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis market or expected to get launched during the study period. The analysis covers Systemic Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Systemic Sclerosis Therapies and Key Companies

*
OFEV (nintedanib): Boehringer Ingelheim

*
ACTEMRA (tocilizumab): Roche

*
RITUXAN (rituximab): Zenyaku Kogyo/Chugai Pharmaceutical

*
LUMICEF (brodalumab/KHK-4827): Kyowa Kirin

*
BENLYSTA (belimumab): GSK

*
SAPHNELO (anifrolumab): AstraZeneca

*
UPLIZNA (inebilizumab/MT-0551): Amgen (Horizon Therapeutics)/ Mitsubishi Tanabe Pharma

*
Vixarelimab (RG6536): Roche (Genentech)/ Kiniksa Pharmaceuticals

*
Avenciguat (BI 685509): Boehringer Ingelheim

*
KYV 101: Kyverna Therapeutics

*
CABA-201: Cabaletta Bio

*
RO7303509: Roche (Genentech)

Discover more about therapies set to grab major Systemic Sclerosis market share @ Systemic Sclerosis Treatment Landscape [https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Systemic Sclerosis Market Strengths

*
Based on the role of B cells and the published clinical datas with CD19-CAR T therapy in systemic sclerosis, it is believed that CABA-201 may transform the treatment for systemic sclerosis.

*
Kyowa Kirin submitted an sNDA for brodalumab in treating systemic sclerosis. Launch of this drug will boost the systemic sclerosis market.

Systemic Sclerosis Market Opportunities

*
Development of a potential biomarker that allows for tracking and predicting the severity and potential progress of the disease and the effectiveness of any therapeutic intervention

*
Since pulmonary involvement is a leading cause of morbidity and mortality in SSc, there is a need for more effective treatments that can stabilize or improve lung function and delay disease progression.

Scope of the Systemic Sclerosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Systemic Sclerosis Companies: Boehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharmaceutical, Kyowa Kirin, GSK, AstraZeneca, Amgen, Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, Kyverna Therapeutics, Cabaletta Bio, and others

*
Key Systemic Sclerosis Therapies: OFEV (nintedanib), ACTEMRA (tocilizumab), RITUXAN (rituximab), LUMICEF (brodalumab/KHK-4827), BENLYSTA (belimumab), SAPHNELO (anifrolumab), UPLIZNA (inebilizumab/MT-0551), Vixarelimab (RG6536), Avenciguat (BI 685509), KYV 101, CABA-201, RO7303509, and others

*
Systemic Sclerosis Therapeutic Assessment: Systemic Sclerosis current marketed and Systemic Sclerosis emerging therapies

*
Systemic Sclerosis Market Dynamics: Systemic Sclerosis market drivers and Systemic Sclerosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Systemic Sclerosis Unmet Needs, KOL's views, Analyst's views, Systemic Sclerosis Market Access and Reimbursement

To know more about Systemic Sclerosis companies working in the treatment market, visit @ Systemic Sclerosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/systemic-sclerosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Systemic Sclerosis Market Report Introduction

2. Executive Summary for Systemic Sclerosis

3. SWOT analysis of Systemic Sclerosis

4. Systemic Sclerosis Patient Share (%) Overview at a Glance

5. Systemic Sclerosis Market Overview at a Glance

6. Systemic Sclerosis Disease Background and Overview

7. Systemic Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Sclerosis

9. Systemic Sclerosis Current Treatment and Medical Practices

10. Systemic Sclerosis Unmet Needs

11. Systemic Sclerosis Emerging Therapies

12. Systemic Sclerosis Market Outlook

13. Country-Wise Systemic Sclerosis Market Analysis (2020-2034)

14. Systemic Sclerosis Market Access and Reimbursement of Therapies

15. Systemic Sclerosis Market Drivers

16. Systemic Sclerosis Market Barriers

17. Systemic Sclerosis Appendix

18. Systemic Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-sclerosis-market-rapid-increment-driven-by-innovation-by-2034-delveinsight-boehringer-ingelheim-roche-zenyaku-kogyo-chugai-pharma-kyowa-kirin-gsk-astrazeneca-amgen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.